Earnings call transcript: BASF lifts 2026 outlook after strong Q3, shares slip

BASF raised its 2026 EBITDA-before-special-items outlook to €7.4 billion–€7.8 billion from €7.0 billion–€7.6 billion after Q3 EBITDA rose about 15% year over year to €1.6 billion. First-nine-month free cash flow remained negative at €1.0 billion, and the full-year free-cash-flow target was unchanged at €1.5 billion–€2.3 billion; 2026 capex is now expected at €2.8 billion–€2.9 billion. CEO Markus Kamieth described Evonik as BASF’s preferred potential acquisition target but said a transaction is not a requirement and would proceed only if value-accretive; BASF gave no formal 2027 guidance. Shares were down 0.68% at $14.53.

Analysis

The key quality question is whether BAS’s earnings recovery is becoming self-sustaining or is still leaning on disruption-driven pricing. Management’s own Q4 framing—seasonally softer demand after supply chains adapt, alongside higher energy costs—raises the risk that recent price gains fade before cost savings fully carry earnings. That makes cash conversion the near-term test, not the EBITDA raise: the unchanged FCF range requires a strong Q4 collection, while inventory release remains exposed to feedstock prices. Failure to convert earnings into cash would weaken the credibility of buybacks and the deleveraging narrative.

Lower capex may support cash generation beyond 2026, but the stated multi-year envelope matters: persistent underspend could improve returns if existing capacity is sufficient, or defer maintenance/growth investment and constrain later volumes. Separately, the Evonik combination is a potential catalyst, not a bankable synergy case. BAS’s insistence on financial discipline limits downside from overpaying, but deal speculation can lift EVK before terms—and financing, approval and integration risks—are known. The proposed Agricultural Solutions IPO is a later portfolio catalyst, though weak pricing and volumes argue against treating a separation as an immediate earnings fix.

Near term, BAS’s muted reaction is consistent with investors discounting the guidance raise until cash arrives. Over 1–3 months, Q4 collections, energy/feedstock moves and any Evonik transaction detail dominate. Over 6–18 months, the thesis depends on restructuring gains and normalized margins outweighing persistent restructuring costs and China competition. Contrarian risk: investors may over-credit higher pricing as a durable recovery; conversely, if cash conversion and cost reductions hold, the gradual margin path could be underappreciated.

Key Decisions for Investors

• Do not chase the EBITDA raise. Keep BAS as a watch/conditional long: add only after Q4 reporting demonstrates cash conversion and the 2026 FCF range remains credible. Falsifier: missed FCF guidance or working capital fails to unwind.
• Track BAS cash conversion against feedstock prices and receivables collections; the stated Q4 recovery is a management expectation, not yet verified. A sustained rise in inventory days or weaker operating cash flow would undermine the recovery thesis.
• Treat EVK as event-driven, not a confirmed takeout. Avoid positioning on assumed deal terms; reassess only after credible transaction economics and financing are disclosed. No defensible BAS/EVK pair trade without those terms.
• Watch the November 24 Capital Markets Day for the capex baseline, Agricultural Solutions separation milestones and 2027 operating assumptions. If lower capex proves durable without erosion in utilization or maintenance, it strengthens the cash-return case; evidence of deferred investment needs would reverse it.